Literature DB >> 2818016

Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Y Tokano1, A Murashima, Y Takasaki, H Hashimoto, K Okumura, S Hirose.   

Abstract

The concentration of soluble interleukin 2 receptor (IL-2R) was determined in the serum of 54 patients with systemic lupus erythematosus (SLE) by an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies with the IL-2R. Concentrations of soluble IL-2R in the serum of the patients with SLE (study group) were significantly higher than in 20 normal subjects (control group). The relation between concentrations of soluble IL-2R and clinical findings was investigated. The concentration of soluble IL-2R showed no particular relation with the clinical manifestations and did not correlate with the level of anti-DNA antibody or CH50. Significant correlation between the concentration of soluble IL-2R and disease activity did exist, however. Furthermore, the concentration of soluble IL-2R in some cases changed simultaneously with the disease activity. Thus the concentration of soluble IL-2R may serve as a new clinical indicator of disease activity in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2818016      PMCID: PMC1003885          DOI: 10.1136/ard.48.10.803

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Measurement of serum DNA-binding activity in systemic lupus erythematosus.

Authors:  T Pincus; P H Schur; J A Rose; J L Decker; N Talal
Journal:  N Engl J Med       Date:  1969-09-25       Impact factor: 91.245

Review 2.  T-cell growth factor.

Authors:  K A Smith
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

3.  Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

4.  Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Authors:  Y P Huang; L H Perrin; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

5.  Soluble interleukin-2 receptors in systemic lupus erythematosus.

Authors:  R E Wolf; W G Brelsford
Journal:  Arthritis Rheum       Date:  1988-06

6.  Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus.

Authors:  T Sakane; A D Steinberg; I Green
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

7.  In vitro synthesis of rat fibrinogen: identification of preA alpha, preB beta, and pre gamma polypeptides.

Authors:  J M Nickerson; G M Fuller
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

8.  Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features.

Authors:  J S Smolen; T M Chused; W M Leiserson; J P Reeves; D Alling; A D Steinberg
Journal:  Am J Med       Date:  1982-05       Impact factor: 4.965

9.  Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization.

Authors:  D T Yu; R J Winchester; S M Fu; A Gibofsky; H S Ko; H G Kunkel
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells.

Authors:  H S Ko; S M Fu; R J Winchester; D T Yu; H G Kunkel
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  14 in total

1.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

Authors:  P Airò; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

2.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

3.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.

Authors:  Y Tokano; S Miyake; N Kayagaki; K Nozawa; S Morimoto; M Azuma; H Yagita; Y Takasaki; K Okumura; H Hashimoto
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

4.  Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus.

Authors:  K Abe; Y Takasaki; C Ushiyama; J Asakawa; T Fukazawa; M Seki; M Hirashima; M Ogaki; H Hashimoto
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

5.  Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis.

Authors:  C Y Tsai; T H Wu; K H Sun; W M Lin; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

6.  Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis.

Authors:  Y Tokano; Y Kanai; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 7.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Assessment of lupus: where are we now?

Authors:  E Hay; C Gordon; P Emery
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

9.  Soluble CD4, CD8 in patients with polymyositis/dermatomyositis.

Authors:  Y Tokano; T Obara; H Hashimoto; K Okumura; S Hirose
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

10.  Protein heterogeneity in the human Ro/SSA ribonucleoproteins. The 52- and 60-kD Ro/SSA autoantigens are encoded by separate genes.

Authors:  K Itoh; Y Itoh; M B Frank
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.